Pfizer has extended its chain of drug discovery innovation centers in Boston, New York, and San Francisco to include San Diego. UC San Diego Health Sciences says today it signed a partnership agreement with Pfizer that could be worth as much as $50 million in funding from the New York pharmaceutical giant over the next five years.
Pfizer established its Centers for Therapeutic Innovation (CTI) as part of a drive for more open, collaborative, and entrepreneurial-minded research, with the goal of dramatically slashing years from the time spent in drug development. The local CTI staff will include researchers from Pfizer, the UC San Diego School of Medicine, Skaggs School of Pharmacy and Pharmaceutical Sciences, and other UCSD scientists.
The partnership is intended to build on the expertise in translational medicine that UC San Diego boosted last year, when its Clinical and Translational Research Institute received a five-year, $37.2 million award from the National Center for Research Resources, part of the National Institutes of Health.
Under the partnership, Pfizer will open some of its antibody libraries and technologies to UC San Diego scientists. The pharmaceutical company also agreed to help support the pre-clinical and clinical development of sponsored programs. Pfizer grants intellectual property rights to its partners, who also are granted milestone payments and royalties based on how well drug candidates advance.
By posting a comment, you agree to our terms and conditions.